Cheung Hoi Yu
Director/Board Member bij YNBY INTERNATIONAL LIMITED
Profiel
Dr. Cheung Hoi Yu is an Independent Non-Executive Director at YNBY International Ltd., an Independent Non-Executive Director at Tiger Jade Acquisition Co., an Independent Director at Keen Vision Acquisition Corp., an Independent Non-Executive Director at Sirnaomics Ltd., a Member at The Stock Exchange of Hong Kong Ltd., a Chairman at Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Allia, a Chairman at Hong Kong Biotechnology Organization, a Professor at Peking University, a Chief Executive Officer & Director at Hai Kang Life Corp.
Ltd.
and an Independent Non-Executive Director at Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd.
He is on the Board of Directors at YNBY International Ltd., Tiger Jade Acquisition Co., Keen Vision Acquisition Corp., Sirnaomics Ltd., CR-CP Life Science Fund, Gordon Research Conferences, Asian Fund For Cancer Research Ltd., BIOHK Ltd., Hong Kong Dna Chips Ltd., Hai Kang Life Corp.
Ltd., Angenomics Ltd., Dna-Tech Ltd., Hong Kong-Taiwan Youth Exchange Promotion Association Ltd., Sun Yat-Sen Cultural Foundation Ltd., The Hong Kong Chinese Importers' & Exporters' Association and Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd.
Dr. Yu was previously employed as a Co-Chairman by Hong Kong Council For Testing & Certification, a Non-Executive Director by Hong Kong Science & Technology Parks Corp., a Professor by Stanford University, a Professor by The Hong Kong University of Science & Technology, and a Professor by Peking University Health Science Center.
He also served on the board at Chinese Neuroscience Society and Beijing Society For Neuroscience.
He received his undergraduate degree from the University of Saskatchewan, a graduate degree from the University of Saskatchewan and a doctorate degree from the University of Saskatchewan.
Actieve functies van Cheung Hoi Yu
Bedrijven | Functie | Begin |
---|---|---|
KEEN VISION ACQUISITION CORPORATION | Director/Board Member | 01-10-2021 |
SIRNAOMICS LTD. | Director/Board Member | 01-07-2021 |
YNBY INTERNATIONAL LIMITED | Director/Board Member | 21-11-2023 |
Hong Kong-Taiwan Youth Exchange Promotion Association Ltd. | Director/Board Member | - |
The Stock Exchange of Hong Kong Ltd.
The Stock Exchange of Hong Kong Ltd. Investment Banks/BrokersFinance HKEx is the holding company of The Stock Exchange of Hong Kong Limited, Hong Kong Futures Exchange Limited and Hong Kong Securities Clearing Company Limited. It brings together the market organisations which have transformed Hong Kong's financial services industry from a domestically focused market to become a central market place in Asia attracting investment funds from all over the world. HKEx was listed in June 2000 following the integration of Hong Kong's securities and derivatives markets. As a market-driven organisation, answerable to its shareholders, HKEx competes vigorously for opportunities in the region and around the world. HKEx's operations are organised into focused units, directly supervised and controlled by management and the board of directors. The board, the highest decision-making body, determines HKEx's objectives, missions, strategies, policies and business plan and monitors their implementation by management. In its role as the operator and frontline regulator of the central securities and derivatives marketplace in Hong Kong, HKEx regulates listed issuers; administers listing, trading and clearing rules; and provides services, primarily at the wholesale level, to customers of the exchanges and clearing houses, including issuers and intermediaries - investment banks or sponsors, securities and derivatives brokers, custodian banks and information vendors - who service the investor directly. These services comprise trading, clearing and settlement, depository and nominee services, and information services. | Corporate Officer/Principal | 01-04-2018 |
Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd.
Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sirnaomics, Inc., Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. is a Chinese company that develops nucleic acid drugs. The private company is based in Suzhou, China. The company was founded in 2008 by Yang Lu, David Mark Evans. Yang Lu has been the CEO since 2008. | Director/Board Member | - |
Dna-Tech Ltd. | Director/Board Member | - |
Angenomics Ltd. | Director/Board Member | - |
Hong Kong Dna Chips Ltd. | Founder | 01-04-2007 |
░░░ ░░░░░░░ ░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░ ░░░░ ░░░░ ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Eerdere bekende functies van Cheung Hoi Yu
Bedrijven | Functie | Einde |
---|---|---|
░░░░ ░░░░ ░░░░░░░ ░░░ ░░░░░░░ ░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░ ░░░░░░░ ░░░░░ ░░░░░░░░░░ ░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░ ░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Cheung Hoi Yu
University of Saskatchewan | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
YNBY INTERNATIONAL LIMITED | Finance |
SIRNAOMICS LTD. | Health Technology |
KEEN VISION ACQUISITION CORPORATION | Finance |
Bedrijven in privébezit | 19 |
---|---|
Gordon Research Conferences | |
The Stock Exchange of Hong Kong Ltd.
The Stock Exchange of Hong Kong Ltd. Investment Banks/BrokersFinance HKEx is the holding company of The Stock Exchange of Hong Kong Limited, Hong Kong Futures Exchange Limited and Hong Kong Securities Clearing Company Limited. It brings together the market organisations which have transformed Hong Kong's financial services industry from a domestically focused market to become a central market place in Asia attracting investment funds from all over the world. HKEx was listed in June 2000 following the integration of Hong Kong's securities and derivatives markets. As a market-driven organisation, answerable to its shareholders, HKEx competes vigorously for opportunities in the region and around the world. HKEx's operations are organised into focused units, directly supervised and controlled by management and the board of directors. The board, the highest decision-making body, determines HKEx's objectives, missions, strategies, policies and business plan and monitors their implementation by management. In its role as the operator and frontline regulator of the central securities and derivatives marketplace in Hong Kong, HKEx regulates listed issuers; administers listing, trading and clearing rules; and provides services, primarily at the wholesale level, to customers of the exchanges and clearing houses, including issuers and intermediaries - investment banks or sponsors, securities and derivatives brokers, custodian banks and information vendors - who service the investor directly. These services comprise trading, clearing and settlement, depository and nominee services, and information services. | Finance |
Hong Kong Science & Technology Parks Corp.
Hong Kong Science & Technology Parks Corp. Miscellaneous Commercial ServicesCommercial Services Hong Kong Science & Technology Parks Corp. provides research and development in fields of science and technology. It helps the science and technology companies under its care by offering them both state-of-the-art facilities as well as value-added services including research and development offices, infrastructure, market-led laboratories, and technical centres with professional support services. The company was founde din 2002 and is headquartered in Hong Kong. | Commercial Services |
The Hong Kong Chinese Importers' & Exporters' Association | |
Hong Kong Council For Testing & Certification | |
Hong Kong Biotechnology Organization | |
CR-CP Life Science Fund
CR-CP Life Science Fund Investment ManagersFinance CR-CP Life Science Fund is a venture capital fund invests companies located in China. It targets companies operating in the fields of diagnose, medical equipment and health technology. | Finance |
Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd.
Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sirnaomics, Inc., Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. is a Chinese company that develops nucleic acid drugs. The private company is based in Suzhou, China. The company was founded in 2008 by Yang Lu, David Mark Evans. Yang Lu has been the CEO since 2008. | Health Technology |
Hai Kang Life Corp. Ltd.
Hai Kang Life Corp. Ltd. Medical/Nursing ServicesHealth Services Hai Kang Life Corp. Ltd. operates as a healthcare platform. The Chinese company was founded by Cheung Hoi Yu and Cheung Hoi Yu has been the CEO since incorporation. | Health Services |
Asian Fund For Cancer Research Ltd. | |
Tiger Jade Acquisition Co.
Tiger Jade Acquisition Co. Financial ConglomeratesFinance Tiger Jade Acquisition Co. is a blank check company. It engages in the business of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 5, 2022 and is headquartered in Hong Kong. | Finance |
Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Allia | |
Hong Kong Dna Chips Ltd. | |
Angenomics Ltd. | |
Sun Yat-Sen Cultural Foundation Ltd. | |
Dna-Tech Ltd. | |
Chinese Neuroscience Society | |
Beijing Society For Neuroscience | |
Hong Kong-Taiwan Youth Exchange Promotion Association Ltd. |